Long Ideas - The results of 4 head-to-head trials comparing the safety and efficacy of Affymax’s (AFFY) Omontys (pegesanitide) and. Amgen’s leading erythropoietin stimulating agents (ESAs), Epogen and … Continue Reading
Read NowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read NowMost Popular - The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and … Continue Reading
Read NowLong Ideas - XenoPort (NASDAQ:XNPT) will deliver Phase III trial results for its lead pipeline candidate, Arbaclofen Placarbil, in early 2Q, and the company is moving forward on … Continue Reading
Read NowLong Ideas - Shares of Navidea Biopharmaceuticals (NASDAQ:NAVB) are ready to climb as the PDUFA (FDA action) date for the company’s lead product, Lymphoseek, is approaching. This is … Continue Reading
Read NowLong Ideas - As the world’s largest biotechnology company, with a market capitalization well on its way to $70 billion, Amgen (NASDAQ:AMGN) represents the “old guard” of biotechnology. … Continue Reading
Read NowMost Popular - We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some … Continue Reading
Read Now